U.S. Luxury Stock News

Moderna (NasdaqGS:MRNA) has received European Medicines Agency approval for its mRNA flu vaccine, following efficacy data in older adults. In the U.S., the FDA initially declined to review the same vaccine application, despite positive clinical results cited by the company. Moderna’s CEO has warned that the company may scale back late-stage development in the U.S., pointing to concerns about regulatory and political pressures. The split between EU and U.S. regulators is raising questions...

Why Capital One Financial (COF) is on investors’ radar today Capital One Financial (COF) is drawing fresh attention after recent share price weakness, with the stock showing negative returns over the past week, month, and past 3 months despite a positive 1 year total return. See our latest analysis for Capital One Financial. With the latest share price at $176.10, the short-term picture is weak, as shown by a 1-month share price return decline of 14.43%, even though the 1-year total...

Verra Mobility, NasdaqCM:VRRM, is reporting long term sales growth alongside pressure on free cash flow margins. Recent quarterly results show weaker profitability, prompting questions about investment needs and cost control. Investor sentiment has cooled, with the share price at $13.88 and a 37.8% decline year to date. For shareholders, the story around Verra Mobility is no longer just about sales momentum. The stock is down 37.8% year to date and 31.3% over the past year, with the current...

In March 2026, Smithfield Foods reported higher fourth-quarter and full-year 2025 results, issued 2026 guidance for low-single-digit sales growth, announced a quarterly dividend of US$0.3125 per share, and outlined an agreement to acquire the Nathan's Famous packaged meats brand while continuing to evaluate additional M&A opportunities. A key takeaway for investors is Smithfield Foods’ record 2025 operating profit of US$1.30 billion and margin expansion to 8.6%, highlighting improved...

Earlier in 2026, Duolingo reported strong results with more than 50 million daily active users and solid margins, while announcing a shift to reinvest more heavily in AI-driven product development and user growth, targeting roughly 20% daily active user expansion and aiming for 100 million daily users by 2028. This decision to emphasize scale over near-term profitability, despite already very large user growth and robust free cash flow margins in recent years, raised questions about how the...

If you are wondering whether Hershey at around US$213.73 is still a fair deal or already pricing in a lot of optimism, you are asking the right question that this valuation focused piece will tackle. Over the past year the stock has returned 29.7%, with a 17.2% gain year to date, even as the last month shows a 6.9% decline and the last three years sit at a 8.7% loss. Recent coverage has highlighted Hershey's ongoing position as a major packaged foods name, and investors have been weighing...

Williams-Sonoma (NYSE:WSM) is launching its first major retail expansion in more than ten years, adding new and refreshed stores across key locations. The company is also rolling out a high-profile collaboration with lifestyle brand Hill House Home for its Pottery Barn Kids and Pottery Barn Teen banners. The expansion and partnership are positioned alongside Williams-Sonoma's existing digital and direct-to-consumer strengths. Williams-Sonoma, known for its home, kitchen, and specialty...

Rosen Law Firm has filed a class action lawsuit against Lufax Holding Ltd., accusing the company of misleading investors between April 7, 2023 and January 26, 2025 by allegedly misstating financial results and lacking adequate internal controls. The case centers on whether Lufax’s disclosures about its business and financial reporting had a reasonable basis, raising important questions about its governance and transparency practices. We’ll now examine how concerns over Lufax’s internal...

Spero Therapeutics (SPRO) closed FY 2025 with fourth quarter revenue of US$41.3 million and basic EPS of US$0.56, alongside trailing twelve month revenue of US$66.8 million and EPS of roughly US$0.15 that mark a shift into profitability over the period. Over recent quarters, the company has seen revenue range from US$5.4 million to US$41.3 million with quarterly EPS moving from a loss of about US$0.25 per share at the start of FY 2025 to a profit in the latest quarter, providing a clearer...

Bitgo Holdings FY 2025 Earnings Snapshot Bitgo Holdings (BTGO) just posted its FY 2025 results with third quarter revenue of about US$5.8 billion, Basic EPS of US$0.19 and net income of US$6.8 million. Trailing twelve month revenue stood at roughly US$11.1 billion with Basic EPS of US$1.49 and net income of US$57.1 million. The company has seen quarterly revenue move from US$817.8 million in FY 2024 Q3 to US$5.8 billion in FY 2025 Q3, and Basic EPS shift from US$0.11 in FY 2024 Q1 and Q2 to...

KKR (NYSE:KKR) agreed to acquire Nothing Bundt Cakes, adding a branded bakery chain to its consumer-focused holdings. The firm realized an estimated ~15x return on its investment in CoolIT Systems through a sale to Ecolab. Management has outlined ambitious asset growth goals and plans to enter additional investment sectors at recent investor events. KKR, a global investment firm listed on the NYSE under the ticker KKR, is active across private equity, credit, and infrastructure. The...

Gilat Satellite Networks (GILT) is back in focus after announcing a joint SATELLITE 2026 demonstration with Amazon Web Services and partners, along with fresh U.S. Army service orders through its Gilat DataPath unit. See our latest analysis for Gilat Satellite Networks. The latest U.S. Army orders and the upcoming SATELLITE 2026 cloud modem demo arrive after a 1 year total shareholder return of 137.5% and a 3 year total shareholder return of roughly 3x. At the same time, the recent 7 day...

Stratus Properties (STRS) has just posted another tough quarter, with Q3 FY 2025 revenue of US$5.0 million and a basic EPS loss of US$0.62, alongside a net income loss of US$5.0 million. The trailing twelve month picture shows total revenue of US$31.9 million and a net income loss of US$8.1 million. Over recent periods the company has seen quarterly revenue move between US$4.9 million and US$11.6 million, with basic EPS ranging from a small profit of US$0.03 per share to losses of up to...

If you are wondering whether Tidewater's current share price really reflects its underlying worth, you are not alone. The stock last closed at US$82.40, with returns of 13.7% over 7 days, 4.9% over 30 days, 57.8% year to date, and 89.6% over 1 year that many investors will be paying close attention to. Recent news coverage has focused on Tidewater's role within the energy services space and how investors are reacting to sector wide sentiment. This context helps frame why the recent price...

Newsmax (NMAX) has just posted its FY 2025 numbers with third quarter revenue of US$45.3 million and a basic EPS loss of US$0.03, set against trailing 12 month revenue of US$184.7 million and a basic EPS loss of US$1.29 that keeps the story firmly in loss making territory. Over recent quarters the company has seen revenue move from US$39.2 million in Q2 FY 2024 to the current US$45.3 million. Quarterly basic EPS has ranged from a loss of US$1.27 in Q1 FY 2024 to a loss of US$0.03 in Q3 FY...

CapsoVision (CV) closed FY 2025 with fourth quarter revenue of US$3.9 million, a basic EPS loss of US$0.16 per share, and trailing twelve month revenue of US$13.6 million alongside a trailing EPS loss of US$1.03 per share. Over recent quarters, revenue has moved from US$3.5 million in Q3 2025 and US$3.3 million in Q2 2025 to the latest US$3.9 million print. Basic EPS losses shifted from US$0.17 and US$2.02 over those same periods to US$0.16, leaving investors focused on how quickly margins...

Carnival Corporation (CCL) has kicked off Q1 2026 following a solid run through 2025, with Q4 2025 revenue of US$6.3 billion, basic EPS of US$0.32 and net income of US$422 million framing the latest set of numbers. Over the past few quarters, revenue has moved from US$5.9 billion in Q4 2024 to US$6.3 billion in Q2 2025 and again US$6.3 billion in Q4 2025, while quarterly basic EPS has ranged from a loss of US$0.06 in Q1 2025 to US$1.41 in Q3 2025. This has set up a story where rising trailing...

Privia Health Group (PRVA) has been drawing attention after recent share price pressure, with the stock showing negative returns over the past month and past 3 months as investors reassess expectations. See our latest analysis for Privia Health Group. With the latest share price at $20.02, the stock’s 30 day share price return of 11.61% and year to date share price return of a 14.66% decline sit alongside a 3 year total shareholder return of a 27.49% decline, pointing to fading momentum as...

If you are wondering whether Solventum's current share price still reflects its underlying worth, you are not alone. Many investors are asking the same question as they reassess what counts as good value in healthcare. Over the past month, Solventum's share price moved from recent levels to close at US$62.76, with a 7 day return of a 4.6% decline and a 30 day return of a 16.4% decline that adds to a 20.6% decline year to date and a 16.0% decline over the last year. These moves have come as...

Index removal puts fresh focus on Clorox shares Clorox (CLX) has been removed from the FTSE All-World Index (USD), an index-level change that can prompt portfolio rebalancing by benchmarked funds and encourage investors to reassess how the stock fits within their broader allocations. See our latest analysis for Clorox. At a latest share price of $102.04, Clorox has a 30 day share price return of a 19.17% decline, alongside a 1 year total shareholder return of a 27.38% loss, indicating...

SKYX Platforms (SKYX) closed out FY 2025 with Q4 revenue of about US$24.9 million, a basic EPS loss of US$0.07, and a net income loss of roughly US$8.2 million, while the trailing twelve months showed revenue of about US$92.0 million against a net loss of around US$34.5 million and basic EPS of US$0.32 in losses. Over recent quarters the company has seen revenue move from roughly US$23.7 million in Q4 2024 to US$24.9 million in Q4 2025. Quarterly basic EPS losses shifted from about US$0.11 to...

If you are wondering whether VinFast Auto's current share price really reflects what the business is worth, you are not alone. That is exactly what this valuation focused review will tackle. The stock recently closed at US$3.39, with returns of 18.5% over 7 days, 2.7% over 30 days, 0.3% year to date and 0.0% over the last year, alongside a 67.0% decline over 3 years. Recent headlines around VinFast Auto have continued to keep the company on investors' radar and have added fresh context to...

If you are wondering whether New York Times at around US$82.79 is attractively priced or already reflecting high expectations, it helps to break the story down into what the recent share price is really telling you. The stock has delivered returns of 2.2% over the last 7 days, 7.0% over the last 30 days, 18.6% year to date, 71.1% over 1 year, 120.2% over 3 years, and 72.4% over 5 years. This puts recent performance front and center for anyone thinking about value and risk. Recent news around...

Insmed recently reported positive topline Phase 3b ENCORE results showing that adding once-daily ARIKAYCE to standard multidrug therapy improved respiratory symptoms and culture conversion rates in largely treatment-naïve MAC lung disease patients, with a safety profile consistent with prior experience. The company now plans supplemental regulatory filings in the U.S. and Japan in the second half of 2026, aiming to expand ARIKAYCE’s label from a refractory niche into the much larger...